
Phase 1 Data Show Early Promise for SYNC-T Therapy SV-102 in Refractory Prostate Cancer; Phase 2 LEGION-100 Trial Ongoing
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVGN3UXJTSkhoSkNVLUlGblBJcXBpRjRVOUFveE1pbFdJYkhMMjR6THJ3NmJ6OGIxczJWLWRUdTJzenpHZGxVTUVRRWFSUmREMnFjeUgtX1h2VWdzYUJSRXJLQUFHcEFrV2dWTGhFVXdDYnJ1ZG5jdnZHUjhmLW9ENkdHUWF3bmgwbTVOSDhKa21NVVVRS2pmb1RtcG9maWxkVzBXUG9tSXVZM0F2aWphSU55aEhJdy1hMnlxTnlLcnFNeDUzb0syTHp2aTFFNGxuX05R?oc=5" target="_blank">Phase 1 Data Show Early Promise for SYNC-T Therapy SV-102 in Refractory Prostate Cancer; Phase 2 LEGION-100 Trial Ongoing</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>

